Pharmacokinetic and bioequivalence study of a fixed-dose combination of amlodipine besylate and rosuvastatin calcium compared to co-administration of separate tablets in healthy Korean subjects

氨氯地平 药代动力学 生物等效性 药理学 医学 固定剂量组合 不利影响 置信区间 最大值 交叉研究 相伴的 生物利用度 瑞舒伐他汀 泌尿科 瑞舒伐他汀钙 曲线下面积 内科学 血压 安慰剂 替代医学 病理
作者
Jeong-Soo Park,Ji-Young Jeon,Min-Gul Kim
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
被引量:1
标识
DOI:10.5414/cp203554
摘要

A fixed-dose combination (FDC) tablet of amlodipine and rosuvastatin was recently developed for the treatment of concomitant hypertension and dyslipidemia and is anticipated to improve medication compliance.This study was performed to compare the single-dose pharmacokinetic properties and safety of DP-R212 (FDC of amlodipine and rosuvastatin) to those of each agent co-administered in healthy Korean subjects.A total of 36 healthy Korean subjects were enrolled in this randomized, open-label, single-dose, two-treatment, two-way crossover study. During each treatment period, subjects received the test drug (FDC tablet containing amlodipine and rosuvastatin) or reference drugs (individual tablets). Plasma samples were collected pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose. Safety was assessed by the evaluation of adverse events (AEs), laboratory assessments, 12-lead electrocardiograms (ECGs), physical examinations, and vital sign measurements.The 90% confidence intervals (CIs) of the geometric least-square mean ratios of AUClast and Cmax were 0.9796 - 1.0590 and 1.0135 - 1.0981 for amlodipine, and 0.9156 - 1.0490 and 0.8400 - 1.0306 for rosuvastatin, respectively. All AEs were of mild to moderate intensity, and no significant difference was observed in the incidence of AEs between the treatments. Moreover, the pharmacokinetic properties of the test and reference drugs were bioequivalent to each other, satisfying the regulatory criteria (0.8 - 1.25).Both drugs were safe and well tolerated, and the pharmacokinetic profiles were comparable between the treatments.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
倩倩完成签到 ,获得积分10
1秒前
可取完成签到,获得积分10
1秒前
渡劫完成签到,获得积分10
1秒前
大个应助LILI采纳,获得10
5秒前
赘婿应助小雯采纳,获得10
6秒前
文艺月亮完成签到,获得积分10
6秒前
DD应助方仔采纳,获得10
8秒前
林非鹿完成签到 ,获得积分10
10秒前
郁乾完成签到,获得积分10
12秒前
还单身的湘完成签到,获得积分10
13秒前
14秒前
九湖夷上完成签到 ,获得积分10
14秒前
我叫小小孙呀完成签到,获得积分10
15秒前
威武鞅完成签到,获得积分10
15秒前
小谢完成签到,获得积分10
15秒前
Jeson完成签到,获得积分10
15秒前
董卓小蛮腰完成签到,获得积分10
16秒前
浑映之完成签到 ,获得积分10
16秒前
16秒前
JY完成签到,获得积分10
17秒前
wintersss完成签到,获得积分10
17秒前
怕黑的凝旋完成签到 ,获得积分10
18秒前
了尘完成签到,获得积分10
19秒前
roking完成签到,获得积分10
19秒前
隔水一路秋完成签到,获得积分10
20秒前
qian完成签到,获得积分10
20秒前
louis发布了新的文献求助10
21秒前
yongziwu完成签到,获得积分10
23秒前
小雯发布了新的文献求助10
23秒前
晓风残月完成签到,获得积分10
25秒前
25秒前
于是真的完成签到,获得积分10
26秒前
louis完成签到,获得积分10
28秒前
西瓜完成签到 ,获得积分10
28秒前
娟娟加油完成签到 ,获得积分10
29秒前
HonestLiang完成签到,获得积分10
29秒前
YouziBa完成签到,获得积分10
30秒前
萧然完成签到,获得积分10
30秒前
31秒前
31秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513406
关于积分的说明 11167631
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875150
科研通“疑难数据库(出版商)”最低求助积分说明 804671